看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- Q( {7 [# i! `( @+ M4 Z m k3 Q, b! }
- @4 w" U% S( g+ u' k
( g# ~' i0 n" {5 m! {' ]! g5 `
Currently available feasibility data for possible combination strategies. 7 m, J" @/ ~/ X. E) W8 V
————————————————————————————————% i: G5 X% Y `7 b2 r7 l8 I
Combination Feasibility according to preliminary data
( T) R( W T- ?: G——————————————————————————————————
c) [& u; Z6 P4 Q# P% u2 ZBevacizumab + sorafenib Yes, reduced dose " L+ q" ~" O% g. O" ?3 Y0 V
Bevacizumab + sunitinib† No ' S7 [( K, |1 t! i. S! V
Bevacizumab + temsirolimus Yes
; b: x( u+ w& qBevacizumab + everolimus Yes
9 R- _% f8 P& |1 F& |. nSorafenib + sunitinib ?
+ @" Z- c" Z0 M; A; m) mSorafenib + temsirolimus Yes, reduced dose
" t( u* s! P+ i% `* ]' nSorafenib + everolimus Yes, reduced dose
& K( y Q" i6 l L* OSunitinib + temsirolimus† No / [8 y' k! o# p
Sunitinib + everolimus ?
* V! C# y9 a& H6 e0 @Temsirolimus + everolimus ? ( z0 r5 Q) q% T9 z2 }; C
————————————————————/ R- `# A+ i& Y7 F9 X
†Led to US FDA warning.
1 }1 Q! R& E; I0 i?: As yet unattempted combination.* o$ ^4 z) W1 r# P4 I+ ]
|
显身卡
5 H! p- N1 X9 L9 S
